Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Cure51 was founded in March 2022 by Nicolas Wolikow and Simon Istolainen, alongside seasoned entrepreneurs and four world-renowned oncology centers: Gustave Roussy Institute (IGR, Paris - France), Leon Bérard Center (CLB, Lyon - France), Charité Universitätsmedizin (Berlin - Germany), and Vall d'Hebron (VHIO, Barcelona - Spain). The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer. Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 was founded in March 2022 by Nicolas Wolikow and Simon Istolainen, alongside seasoned entrepreneurs and four world-renowned oncology centers: Gustave Roussy Institute (IGR, Paris - France), Leon Bérard Center (CLB, Lyon - France), Charité Universitätsmedizin (Berlin - Germany), and Vall d'Hebron (VHIO, Barcelona - Spain). The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer. Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Nicolas Wolikow lived 4 years in Dubai where he managed International SOS in the UAE and in Middle East and Africa, a leading company in medical services, medical assistance and security services provided to companies in various sectors ranging from Energy and Mining, to Banking, Technology and Hospitality.

About Cure 51

Cure51 is a French 'TechBio' company founded by Nicolas Wolikow and Simon Istolainen, alongside seasoned entrepreneurs and four world-renowned oncology centers: Gustave Roussy Institute (IGR, Paris - France), Leon Bérard Center (CLB, Lyon - France), Charité Universitätsmedizin (Berlin - Germany) and Vall d'Hebron (VHIO, Barcelona - Spain). The collaboration between the private and public sectors is at the core of the Cure51 project, led by a passionate team with expertise in computing, medicine, and biology, and partnered with principal investigators across its network of over 50 leading oncology centers worldwide.

CONTACT: Clara Armand-Delille, clara@thirdeyemedia.press

Logo - https://mma.prnewswire.com/media/2363023/Cure51_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cure51-raises-a-15-million-seed-round-to-harness-the-natural-power-of-cancer-survivors-and-contribute-to-cure-this-life-threatening-disease-302093654.html